Paratek Pharmaceuticals, Inc.

Other

The United States Government as Represented by the Department of Veterans Affairs

Paratek Pharmaceuticals, Inc.-124418

S Ken Tanaka

Amy L Manley

Lynne Garrity-Ryan

Evangelos L Tzanis

Sean M Johnston

Dennis P Molnar

Robert D Arbeit

Thomas J Bigger

Paul McGovern

Michael P Draper

Judith N Steenbergen

William J Hermann, Jr

Carl H Lawyer

Sudhakar S Wagle

Michael Henry Cynamon

Michael N Alekshun

Thomas Steinbach

Stephen Bai

The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.

Methods of treating mycobacterial infections using tetracycline compounds

Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.

Minocycline compounds for biodefense

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)

The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA,-, or combinations thereof.

Minocycline compounds and methods of use thereof

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.

9-aminomethyl minocycline compounds and uses thereof

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA,-, Viridans, or combinations thereof.

Methods and compositions for the treatment ofinfections are described.

[object Object]

A therapeutic method for treating viral infections and chronic fatigue syndrome. The method comprises administering a therapeutically-effective amount of a mammalian liver extract, the extract being characterized by being heat stable, insoluble in acetone and soluble in water.

Growing community of inventors

Bellevue, WA, United States of America

S Ken Tanaka